Treatment with the BCL-2 inhibitor venetoclax, in combination with azacytidine or decitabine47,51,55 or with low dose cytarabine,56,57 is now approved for treatment of newly diagnosed patients with AML who are ineligible for intensive chemotherapy, and MCL-1 inhibitors have entered clinical trials.58 Here, BCL2 is linked to acute myeloid leukemia.